Millennium Management
RYTM icon

Millennium Management’s Rhythm Pharmaceuticals RYTM Stock Holding History

Millennium Management’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$39.3M Buy
451,825
+265,116
+142% +$25.8M 0.02% 1013
2025
Q4 		$20M Buy
186,709
+53,548
+40% +$5.68M 0.01% 1582
2025
Q3 		$13.4M Sell
133,161
-64,949
-33% -$6.03M 0.01% 2082
2025
Q2 		$12.5M Sell
198,110
-19,269
-9% -$1.18M 0.01% 2024
2025
Q1 		$11.5M Buy
217,379
+202,120
+1,325% +$11.2M 0.01% 2044
2024
Q4 		$854K Sell
15,259
-21,718
-59% -$1.2M ﹤0.01% 4334
2024
Q3 		$1.94M Buy
+36,977
New +$1.77M ﹤0.01% 3724
2024
Q1 		– Sell
-34,831
Closed -$1.52M – 6579
2023
Q4 		$1.6M Sell
34,831
-3,941
-10% -$124K ﹤0.01% 3794
2023
Q3 		$889K Buy
+38,772
New +$868K ﹤0.01% 4269
2023
Q2 		– Sell
-546,906
Closed -$9.76M – 6614
2023
Q1 		$9.76M Buy
546,906
+504,608
+1,193% +$12.7M 0.01% 1981
2022
Q4 		$1.23M Buy
+42,298
New +$1.09M ﹤0.01% 3955
2022
Q3 		– Sell
-489,121
Closed -$2.03M – 7430
2022
Q2 		$2.03M Buy
489,121
+128,529
+36% +$704K ﹤0.01% 3691
2022
Q1 		$4.15M Buy
360,592
+46,888
+15% +$412K ﹤0.01% 3131
2021
Q4 		$3.13M Buy
313,704
+96,780
+45% +$1.09M ﹤0.01% 3335
2021
Q3 		$2.83M Buy
216,924
+60,108
+38% +$918K ﹤0.01% 3505
2021
Q2 		$3.07M Sell
156,816
-13,711
-8% -$285K ﹤0.01% 3404
2021
Q1 		$3.63M Buy
+170,527
New +$4.95M ﹤0.01% 2943
2020
Q1 		– Sell
-22,273
Closed -$511K – 4385
2019
Q4 		$511K Sell
22,273
-218,155
-91% -$4.85M ﹤0.01% 3368
2019
Q3 		$5.19M Buy
240,428
+220,573
+1,111% +$4.73M 0.01% 1772
2019
Q2 		$437K Buy
19,855
+11,678
+143% +$295K ﹤0.01% 3325
2019
Q1 		$224K Buy
+8,177
New +$235K ﹤0.01% 3686
2018
Q4 		– Sell
-19,194
Closed -$560K – 4117
2018
Q3 		$560K Sell
19,194
-9,308
-33% -$294K ﹤0.01% 3184
2018
Q2 		$891K Buy
+28,502
New +$779K ﹤0.01% 2905

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Millennium Management's RYTM Position: Q1 2026 in Review

Millennium Management increased its Rhythm Pharmaceuticals (RYTM) stake by 142% in Q1 2026, buying an estimated $25.8M and bringing the position to 451,825 shares worth $39.3M. The position accounts for 0.02% of the portfolio, ranked #1013.

Millennium Management first reported a position in RYTM in Q2 2018 and has held it in 23 quarters since. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Millennium Management held 451,825 shares of Rhythm Pharmaceuticals worth $39.3M as of Q1 2026.
  • Millennium Management bought 265,116 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $25.8M.
  • Rhythm Pharmaceuticals made up 0.02% of Millennium Management's portfolio in Q1 2026, its #1013 holding.
  • Millennium Management first reported a position in Rhythm Pharmaceuticals in Q2 2018 and has held it in 23 quarters since.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.